{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:16:00Z","timestamp":1790957760783,"version":"4.1.0"},"reference-count":48,"publisher":"Journal of Biological Methods","issue":"4","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HPR"],"abstract":"<jats:p>Phenothiazines, a diverse class of drugs, can be used to treat multiple mental health and physical conditions. Phenothiazines have been used for decades to treat mental illnesses, including schizophrenia, mania in bipolar disorder, and psychosis. Additionally, these drugs offer relief for physical illnesses, including migraines, hiccups, nausea, and vomiting in both adults and children. Further research is needed to prove the efficacy of phenothiazines in treating physical symptoms. Phenothiazines are dopaminergic antagonists that inhibit D2 receptors with varying potency. High potency phenothiazines such as perphenazine are used to treat various psychiatric conditions such as the positive symptoms of schizophrenia, the symptoms of psychosis, and mania that can occur with bipolar disorder. Low\/mid potency phenothiazines such as chlorpromazine antipsychotic drugs that have been used to treat schizophrenia and schizophrenia-like disorders since the 1950s and are utilized in numerous disease states. The present investigation aims to elucidate the effects of phenothiazines in clinical practice.<\/jats:p>","DOI":"10.52965\/001c.38930","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T14:56:36Z","timestamp":1669042596000},"page":"1","source":"Crossref","is-referenced-by-count":27,"title":["Phenothiazines and their Evolving Roles in Clinical Practice: A \u00a0 Narrative Review"],"prefix":"10.14440","volume":"10","author":[{"given":"Amber","family":"N. Edinof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Armistead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"A Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"S. Murnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"M. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"D. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5574","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"ref1","series-title":"Handbook of Psychopharmacology","isbn-type":"print","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-1-4613-4042-3_4","article-title":"Neuroleptics: Clinical Use in Psychiatry","volume":"10","author":"John M. Davis","year":"1978","ISBN":"https:\/\/id.crossref.org\/isbn\/9781461340447"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"CD000284","DOI":"10.1002\/14651858.cd000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Clive E Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1465-1858","issn-type":"print"},{"key":"ref3","article-title":"The Complete Drug Reference","author":"W. Martindale","year":"1999"},{"issue":"10","key":"ref4","first-page":"952","article-title":"Perphenazine (Trilafon) Treatment of Psychoses","volume":"77","author":"P.O. O\u2019Reilly","year":"1957","journal-title":"Can Med Assoc J"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"CD003443","DOI":"10.1002\/14651858.cd003443.pub3","article-title":"Perphenazine for schizophrenia","author":"Benno Hartung","year":"2015","journal-title":"Cochrane Database of Systematic Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1465-1858","issn-type":"print"},{"issue":"6","key":"ref6","first-page":"672","article-title":"Managing hiccups","volume":"57","author":"C.J. Woelk","year":"2011","journal-title":"Can Fam Physician"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.1955.02950210005002","article-title":"Chlorpromazine (thorazine) in the treatment of intractable hiccups","volume":"157","author":"Charles E. Friedgood","year":"1955","journal-title":"Journal of the American Medical Association","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9955","issn-type":"print"},{"issue":"6085","key":"ref8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/bmj.2.6085.501","article-title":"Management of intractable hiccup.","volume":"2","author":"B W Williamson","year":"1977","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/acem.13864","article-title":"Prochlorperazine for Treatment of Acute Migraines in Adults","volume":"27","author":"Brit Long","year":"2020","journal-title":"Academic Emergency Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1069-6563","issn-type":"print"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"173553","DOI":"10.1016\/j.ejphar.2020.173553","article-title":"Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review","volume":"887","author":"Micha\u0142 Otr\u0119ba","year":"2020","journal-title":"European Journal of Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"key":"ref11","series-title":"StatPearls","article-title":"Phenothiazine","author":"A. Kidron","year":"2022"},{"issue":"5","key":"ref12","first-page":"633","article-title":"Phenothiazine analgesia--fact or fantasy?","volume":"36","author":"J.L. McGee","year":"1979","journal-title":"Am J Hosp Pharm"},{"issue":"Suppl 8","key":"ref13","first-page":"5","article-title":"An overview of side effects caused by typical antipsychotics","volume":"61","author":"G.W. Arana","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"ref14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15420\/aer.2018.29.2","article-title":"Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest","volume":"7","author":"Serge Sicouri","year":"2018","journal-title":"Arrhythmia &amp; Electrophysiology Review","ISSN":"https:\/\/id.crossref.org\/issn\/2050-3377","issn-type":"print"},{"issue":"6","key":"ref15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/11587800-000000000-00000","article-title":"Assessing QT interval prolongation and its associated risks with antipsychotics","volume":"25","author":"Jimmi Nielsen","year":"2011","journal-title":"CNS Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1172-7047","issn-type":"print"},{"issue":"10","key":"ref16","first-page":"851","article-title":"Management of psychotropic-induced hyperprolactinemia","volume":"11","author":"P.A. Marken","year":"1992","journal-title":"Clin Pharm"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000119265","article-title":"Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology","volume":"33","author":"K.W. Windgassen","year":"1996","journal-title":"Neuropsychobiology","ISSN":"https:\/\/id.crossref.org\/issn\/0302-282X","issn-type":"print"},{"key":"ref18","article-title":"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects","author":"M.D. Jibson","year":"2021","journal-title":"UpToDate"},{"issue":"S1","key":"ref19","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/hup.917","article-title":"Haematological toxicity of drugs used in psychiatry","volume":"23","author":"Robert J. Flanagan","year":"2008","journal-title":"Human Psychopharmacology: Clinical and Experimental","ISSN":"https:\/\/id.crossref.org\/issn\/0885-6222","issn-type":"print"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4292\/wjgpt.v8.i1.26","article-title":"Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity","volume":"8","author":"A Diogo Telles-Correia","year":"2017","journal-title":"World Journal of Gastrointestinal Pharmacology and Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/2150-5349","issn-type":"print"},{"issue":"5","key":"ref21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0536.1986.tb05278.x","article-title":"Photocontact urticaria from chlorpromazine","volume":"14","author":"C. R. Lovell","year":"1986","journal-title":"Contact Dermatitis","ISSN":"https:\/\/id.crossref.org\/issn\/0105-1873","issn-type":"print"},{"issue":"5","key":"ref22","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"J. Muench","year":"2010","journal-title":"Am Fam Physician"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.20471\/acc.2017.56.02.11","article-title":"Drug-Induced Photosensitivity \u2013 a Continuing Diagnostic Challenge","author":"Liborija Lugovi\u0107-Mihi\u0107","year":"2017","journal-title":"ACTA CLINICA CROATICA","ISSN":"https:\/\/id.crossref.org\/issn\/0353-9466","issn-type":"print"},{"issue":"1","key":"ref24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/ajp.123.1.97","article-title":"Five Cases of Pigmentary Retinopathy Associated with Thioridazine Administration","volume":"123","author":"VARANT Hagopian","year":"1966","journal-title":"American Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"5","key":"ref25","first-page":"323","article-title":"Chlorpromazine-induced cataract and corneal pigmentation","volume":"36","author":"S K","year":"2004","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"ref26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/00001648-200011000-00002","article-title":"Are Schizophrenia or Antipsychotic Drugs a Risk Factor for Cataracts?","volume":"11","author":"Ana Ruig\u00f3mez","year":"2000","journal-title":"Epidemiology","ISSN":"https:\/\/id.crossref.org\/issn\/1044-3983","issn-type":"print"},{"issue":"2","key":"ref27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/jcp.0b013e31819a91f1","article-title":"Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs","volume":"29","author":"Mehmet Ozbilen","year":"2009","journal-title":"Journal of Clinical Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"2","key":"ref28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/0090-4295(79)90165-1","article-title":"In vitro study of phenothiazine effects on urinary bladder","volume":"14","author":"Alex E. Finkbeiner","year":"1979","journal-title":"Urology","ISSN":"https:\/\/id.crossref.org\/issn\/0090-4295","issn-type":"print"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"bcr02.2009.1547","DOI":"10.1136\/bcr.02.2009.1547","article-title":"Antipsychotic-induced urinary dysfunction: anticholinergic effect or otherwise?","volume":"2009","author":"S. Saddichha","year":"2009","journal-title":"Case Reports","ISSN":"https:\/\/id.crossref.org\/issn\/1757-790X","issn-type":"print"},{"issue":"5","key":"ref30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1176\/ajp.132.5.532","article-title":"Drug-induced dystonia","volume":"132","author":"C Swett","year":"1975","journal-title":"American Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"4","key":"ref31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s0196-0644(99)80048-1","article-title":"Prochlorperazine induces akathisia in emergency patients","volume":"34","author":"Daniel L Drotts","year":"1999","journal-title":"Annals of Emergency Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0196-0644","issn-type":"print"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors","volume":"8","author":"David A. Sykes","year":"2017","journal-title":"Nature Communications","ISSN":"https:\/\/id.crossref.org\/issn\/2041-1723","issn-type":"print"},{"issue":"13","key":"ref33","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1017\/s0033291717000873","article-title":"Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis","volume":"47","author":"J. Vermeulen","year":"2017","journal-title":"Psychological Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0033-2917","issn-type":"print"},{"issue":"3","key":"ref34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11940-011-0117-x","article-title":"Tardive Dyskinesia","volume":"13","author":"Pratibha G. Aia","year":"2011","journal-title":"Current Treatment Options in Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1092-8480","issn-type":"print"},{"issue":"suppl 10","key":"ref35","first-page":"0","article-title":"The Relationship of Pharmacology to Side Effects","volume":"58","author":"D.E. Casey","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"ref36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40263-015-0262-y","article-title":"Antipsychotic Drug Use and the Risk of Seizures: Follow-up Study with a Nested Case\u2013Control Analysis","volume":"29","author":"Marlene Bloechliger","year":"2015","journal-title":"CNS Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1172-7047","issn-type":"print"},{"issue":"9896","key":"ref37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Stefan Leucht","year":"2013","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"06","key":"ref38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-0033-1347177","article-title":"Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review Part II: Antipsychotics","volume":"46","author":"A. La Torre","year":"2013","journal-title":"Pharmacopsychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0176-3679","issn-type":"print"},{"issue":"3","key":"ref39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1017\/s1092852916000699","article-title":"Neurodevelopmental outcomes in infants exposed in utero to antipsychotics: a systematic review of published data","volume":"22","author":"Salvatore Gentile","year":"2017","journal-title":"CNS Spectrums","ISSN":"https:\/\/id.crossref.org\/issn\/1092-8529","issn-type":"print"},{"issue":"20","key":"ref40","first-page":"2539","article-title":"Antipsychotic agents and pregnant women. A case report","volume":"115","author":"M. Handal","year":"1995","journal-title":"Tidsskr Den Nor Laegeforening Tidsskr Prakt Med Ny Raekke"},{"issue":"1","key":"ref41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1017\/s0033291797005965","article-title":"Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants","volume":"28","author":"K. Yoshida","year":"1998","journal-title":"Psychological Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0033-2917","issn-type":"print"},{"issue":"s380","key":"ref42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0447.1994.tb05828.x","article-title":"Subjective response to neuroleptics and the quality of life: implications for treatment outcome","volume":"89","author":"A. G. Awad","year":"1994","journal-title":"Acta Psychiatrica Scandinavica","ISSN":"https:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"issue":"2","key":"ref43","doi-asserted-by":"publisher","first-page":"CD000459","DOI":"10.1002\/14651858.cd000459.pub3","article-title":"Antipsychotic reduction and\/or cessation and antipsychotics as specific treatments for tardive dyskinesia","author":"Hanna Bergman","year":"2018","journal-title":"Cochrane Database of Systematic Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1465-1858","issn-type":"print"},{"issue":"2","key":"ref44","doi-asserted-by":"publisher","first-page":"CD000307","DOI":"10.1002\/14651858.cd000307","article-title":"Depot fluphenazine for schizophrenia","author":"Clive E Adams","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"ref45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/bf00422403","article-title":"Fluphenazine pharmacokinetics and therapeutic response","volume":"73","author":"Maurice W. Dysken","year":"1981","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"issue":"10","key":"ref46","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1176\/ajp.138.10.1362","article-title":"Fluphenazine decanoate and tardive dyskinesia: a possible association","volume":"138","author":"J.G. Csernansky","year":"1981","journal-title":"American Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"6","key":"ref47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40264-016-0398-9","article-title":"The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis","volume":"39","author":"Melissa Lau Moon Lin","year":"2016","journal-title":"Drug Safety","ISSN":"https:\/\/id.crossref.org\/issn\/0114-5916","issn-type":"print"},{"issue":"64","key":"ref48","first-page":"1329","article-title":"Artificial hibernation by pharmacodynamical and physical means","volume":"59","author":"H. Laborit","year":"1951","journal-title":"Presse Med"}],"container-title":["Health Psychology Research"],"original-title":[],"link":[{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/20250407093558548875869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/20250407093558548875869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T03:31:21Z","timestamp":1760412681000},"score":1,"resource":{"primary":{"URL":"https:\/\/healthpr.org\/journal\/HPR\/10\/4\/10.52965\/001c.38930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.38930","relation":{},"ISSN":["2420-8124"],"issn-type":[{"value":"2420-8124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]}}}